WO2008035377A3 - Novel intermediates for the preparation of camptothecin analogues - Google Patents

Novel intermediates for the preparation of camptothecin analogues Download PDF

Info

Publication number
WO2008035377A3
WO2008035377A3 PCT/IN2007/000381 IN2007000381W WO2008035377A3 WO 2008035377 A3 WO2008035377 A3 WO 2008035377A3 IN 2007000381 W IN2007000381 W IN 2007000381W WO 2008035377 A3 WO2008035377 A3 WO 2008035377A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
salts
camptothecin analogues
novel intermediates
formula
Prior art date
Application number
PCT/IN2007/000381
Other languages
French (fr)
Other versions
WO2008035377A2 (en
Inventor
B Vishnukant
Original Assignee
Shilpa Medicare Ltd
B Vishnukant
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shilpa Medicare Ltd, B Vishnukant filed Critical Shilpa Medicare Ltd
Publication of WO2008035377A2 publication Critical patent/WO2008035377A2/en
Publication of WO2008035377A3 publication Critical patent/WO2008035377A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to novel intermediate compounds of formula (Ia) and its salts thereof, wherein R is an amino protecting group, R1 is selected from the group consisting of hydrogen, an alkyl, araalkyl, hydroxymethyl, carboxymethyl, acyloxymethyl, trialkylsilyl or an N-substituted alkyl amine where nitrogen forms the linking atom. The invention also relates to the use of these novel intermediate compounds of formula (Ia) for the preparation of camptothecin analogues and its salts, more particularly the anti-cancer drug irinotecan and its pharmaceutically accepted salts.
PCT/IN2007/000381 2006-09-18 2007-08-31 Novel intermediates for the preparation of camptothecin analogues WO2008035377A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1704/CHE/2006 2006-09-18
IN1704CH2006 2006-09-18

Publications (2)

Publication Number Publication Date
WO2008035377A2 WO2008035377A2 (en) 2008-03-27
WO2008035377A3 true WO2008035377A3 (en) 2009-01-08

Family

ID=39200977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000381 WO2008035377A2 (en) 2006-09-18 2007-08-31 Novel intermediates for the preparation of camptothecin analogues

Country Status (1)

Country Link
WO (1) WO2008035377A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546573B2 (en) * 2009-11-18 2013-10-01 Cadila Healthcare Limited Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxy-camptothecin hydrochloride trihydrate
CN102643283A (en) * 2012-05-08 2012-08-22 江苏红豆杉生物科技有限公司 Method for preparing irinotecan hydrochloride trihydrate pure product
US8722886B1 (en) * 2012-11-13 2014-05-13 Bionumerik Pharmaceuticals, Inc. Methods for the total chemical synthesis of enantiomerically-pure 7-(2′-trimethylsilyl)ethyl camptothecin
EP2881396A1 (en) * 2013-12-03 2015-06-10 Synbias Pharma AG Method for the synthesis of irinotecan

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089413A1 (en) * 2002-04-17 2003-10-30 Pharmacia Corporation Pharmacia corporation
US20040235878A1 (en) * 2003-05-12 2004-11-25 Scinopharm Taiwan, Ltd. Process for the preparation of 7-alkyl-10-hydroxy-20(S)-camptothecin
US20050208146A1 (en) * 2003-10-30 2005-09-22 Pfizer Inc Novel dosage and administration method for oral camptosar

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089413A1 (en) * 2002-04-17 2003-10-30 Pharmacia Corporation Pharmacia corporation
US20040235878A1 (en) * 2003-05-12 2004-11-25 Scinopharm Taiwan, Ltd. Process for the preparation of 7-alkyl-10-hydroxy-20(S)-camptothecin
US20050208146A1 (en) * 2003-10-30 2005-09-22 Pfizer Inc Novel dosage and administration method for oral camptosar

Also Published As

Publication number Publication date
WO2008035377A2 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
MX2011012627A (en) Substituted aminobutyric derivatives as neprilysin inhibitors.
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
WO2007095174A3 (en) Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
MY145031A (en) N-(aminoheteroaryl)-1h-indole-2carboxamide derivatives, and preparation and therapeutic application thereof
TW200642683A (en) Heterocyclic compound
MX2008014908A (en) Novel heterocyclic compound or salt thereof and intermediate thereof.
SI2091948T1 (en) Novel inhibitors of glutaminyl cyclase
WO2008097459A3 (en) Dual-acting antihypertensive agents
WO2007084914A3 (en) Phenoxy-substituted pyrimidines as adenosine receptor antagonists
MX2009011487A (en) Dual-acting antihypertensive agents.
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2008108380A3 (en) Pyrrole compounds
MX344669B (en) Novel anti-platelet agent.
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
TW200728307A (en) Novel spirochromanone derivatives
WO2007138472A3 (en) Triazolopyridazine derivatives
TW200833675A (en) Nicotinamide derivatives
WO2010011821A3 (en) Dual-acting antihypertensive agents
HK1138262A1 (en) Novel phosphodiesterase inhibitors
MY145066A (en) Methods for treating sexual dysfunction
MX2009003927A (en) Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes.
WO2007109578A3 (en) Substituted gamma lactams as prostaglandin ep2 agonists
JO3067B1 (en) Pyrazolylaminopyridines as inhibitors of fak
WO2008003854A3 (en) Derivatives of 2-benzoyl-imidazopyridines, preparation method thereof and use of same in therapeutics

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07827552

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07827552

Country of ref document: EP

Kind code of ref document: A2